臨床検査62巻1号

2018年01月発行

今月の特集2 心腎連関を理解する

貧血と心腎連関

著者： 今井圓裕¹

所属機関： ¹中山寺いまいクリニック

ページ範囲：P.78 - P.83

Point

●慢性心不全，慢性腎不全は貧血を合併することが多い．

●慢性心不全では鉄欠乏状態にある患者が多く，鉄剤の投与によって心不全は改善する可能性がある．

●慢性腎不全ではエリスロポエチンの相対的欠乏による貧血が多い．

●エリスロポエチンを使用した貧血治療はヘモグロビン（Hb）11.0g/dL未満で開始し，Hb13.0g/dLを超えないように注意する．

参考文献

1）Silverberg DS, Wexler D, Blum M, et al：The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant　18：141-146，2003

2）日本腎臓学会（編）：CKD診療ガイド2012，東京医学社，2012

3）McClellan W, Aronoff SL, Bolton WK, et al：The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin　20：1501-1510，2004

4）Akizawa T, Makino H, Matsuo S, et al：Management of anemia in chronic kidney disease patients: baseline findings from Chronic Kidney Disease Japan Cohort Study. Clin Exp Nephrol　15：248-257，2011

5）Minutolo R, Locatelli F, Gallieni M, et al：Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicenter prospective study in renal clinics. Nephrol Dial Transplant　28：3035-3045，2013

6）Iimori S, Naito S, Noda Y, et al：Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study. Nephrology (Carlton)　20：601-608，2015

7）Tsuchiya K, Nitta K：Hepcidin is a potential regulator of iron status in chronic kidney disease. Ther Apher Dial　17：1-8，2013

8）Lekawanvijit S, Kompa AR, Krum H：Protein-bound uremic toxins: a long overlooked culprit in cardiorenal syndrome. Am J Physiol Renal Physiol　311：F52-F62，2016

9）Nanas JN, Matsouka C, Karageorgopoulos D, et al：Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol　48：2485-2489，2006

10）Jankowska EA, Rozentryt P, Witkowska A, et al：Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J　31：1872-1880，2010

11）Shirazi LF, Bissett J, Romeo F, et al：Role of Inflammation in Heart Failure. Curr Atheroscler Rep　19：27，2017

12）日本透析医学会：2015年版　慢性腎臓病患者における腎性貧血治療のガイドライン．日透析医学会誌　49：89-158，2016

13）Ngo K, Kotecha D, Walters JA, et al：Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev　2010：CD007613，2010

14）Drüeke TB, Locatelli F, Clyne N, et al：Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med　355：2071-2084，2006

15）Singh AK, Szczech L, Tang KL, et al：Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med　355：2085-2098，2006

16）Pfeffer MA, Burdmann EA, Chen CY, et al：A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med　361：2019-2032，2009

17）Kuriyama S, Tomonari H, Yoshida H, et al：Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron　77：176-185，1997

18）Tsubakihara Y, Gejyo F, Nishi S, et al：High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther Apher Dial　16：529-540，2012

19）Tsubakihara Y, Akizawa T, Iwasaki M, et al：High Hemoglobin Levels Maintained by an Erythropoiesis-Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment. Ther Apher Dial　19：457-465，2015

20）Imai E, Maruyama S, Nangaku M, et al：Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). Clin Exp Nephrol　20：71-76，2016

21）Anker SD, Comin Colet J, Filippatos G, et al：Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med　361：2436-2448，2009

22）Swedberg K, Young JB, Anand IS, et al：Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med　368：1210-1219，2013